[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Fontaine J, Thomas L, Balme B, Ronger-Savle S, Traullé C, Petrella T, Dalle S: Haematodermic CD4+CD56+ neoplasm: complete remission after methotrexate-asparaginase treatment. Clin Exp Dermatol; 2009 Jul;34(5):e43-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haematodermic CD4+CD56+ neoplasm: complete remission after methotrexate-asparaginase treatment.
  • Haematodermic neoplasm is a recently recognized condition, characterized by tumour cells expressing CD4, CD56 and CD123.
  • We report the case of a 64-year-old woman who presented with a haematodermic CD4+CD56+CD123+ neoplasm affecting the left cheek; the initial staging was otherwise negative.
  • Despite this early stage of the disease, aggressive treatment including methotrexate-asparaginase and local radiotherapy was proposed as first-line therapy.
  • To date there is no consensus on the first-line treatment for such patients but intensive treatment is probably needed immediately even in cases of localized disease.
  • The response obtained with CHOP (cyclophosphamide, doxyrubicin, vincristine, prednisone) or CHOP-like chemotherapy regimens is disappointing.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Facial Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19508475.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.5.1.1 / Asparaginase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


2. Aromando RF, Heber EM, Trivillin VA, Nigg DW, Schwint AE, Itoiz ME: Insight into the mechanisms underlying tumor response to boron neutron capture therapy in the hamster cheek pouch oral cancer model. J Oral Pathol Med; 2009 May;38(5):448-54
Hazardous Substances Data Bank. (L)-Phenylalanine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insight into the mechanisms underlying tumor response to boron neutron capture therapy in the hamster cheek pouch oral cancer model.
  • OBJECTIVE: The therapeutic success of different boron neutron capture therapy (BNCT) protocols employing the hamster cheek pouch oral cancer model has been previously reported by our laboratory.
  • The inhibitory effect of BPA-BNCT occurred as soon as 1 day post-treatment (P < 0.001).
  • Conversely, the effect of GB-10-BNCT became apparent 7-14 days after therapy (P < 0.001) and was sustained until killed at 30 days post-treatment (P < 0.001). (GB-10 + BPA)-BNCT exerted a rapid and persistent effect, conceivably because of the combined effect of BNCT mediated by both boron compounds.
  • The apoptosis studies did not show differences between the pre-treatment group and any of the BNCT groups.
  • [MeSH-major] Apoptosis / radiation effects. Boron Neutron Capture Therapy / methods. DNA, Neoplasm / radiation effects. Mouth Neoplasms / radiotherapy. Neoplasms, Experimental / radiotherapy
  • [MeSH-minor] Animals. Boron Compounds / therapeutic use. Cheek. Cricetinae. Disease Models, Animal. Drug Carriers. In Situ Nick-End Labeling. Mesocricetus. Phenylalanine / analogs & derivatives. Phenylalanine / therapeutic use. Radiation Dosage. Radiation-Sensitizing Agents. Radiopharmaceuticals / therapeutic use

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. BORON COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19141057.001).
  • [ISSN] 1600-0714
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Boron Compounds; 0 / DNA, Neoplasm; 0 / Drug Carriers; 0 / Radiation-Sensitizing Agents; 0 / Radiopharmaceuticals; 47E5O17Y3R / Phenylalanine
  •  go-up   go-down


3. Mukai HY, Okoshi Y, Shimizu S, Katsura Y, Takei N, Hasegawa Y, Kojima H, Mori N, Nagasawa T: Successful treatment of a patient with subcutaneous panniculitis-like T-cell lymphoma with high-dose chemotherapy and total body irradiation. Eur J Haematol; 2003 Jun;70(6):413-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of a patient with subcutaneous panniculitis-like T-cell lymphoma with high-dose chemotherapy and total body irradiation.
  • A 24-yr-old man was referred for fever, right cheek swelling, subcutaneous tumor and liver dysfunction.
  • Physical examination showed an elastic hard subcutaneous tumor on the right cheek, left axillary lymph node swelling and multiple small subcutaneous tumors in the trunk.
  • Biopsy of the subcutaneous tumor showed proliferation of medium-sized cells with abundant clear cytoplasm and hyperchromatic nuclei among the subcutaneous fat tissues.
  • After three courses of the chemotherapy, he was further treated with high-dose chemotherapy and total body irradiation (TBI) with autologous peripheral blood stem cell rescue.
  • We consider that SPTCL with hemophagocytosis is an extremely aggressive disease, and high-dose chemotherapy and TBI should be included for the choice of the treatment.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / diagnosis. Lymphoma, T-Cell, Peripheral / therapy. Panniculitis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Examination. Humans. Magnetic Resonance Imaging. Male. Neoplasm, Residual / diagnosis. Peripheral Blood Stem Cell Transplantation. Remission Induction / methods. Subcutaneous Tissue / pathology. Whole-Body Irradiation


Advertisement
4. Vereecken P, Heenen M: Recurrent lentigo maligna melanoma: regression associated with local azelaic acid 20%. Int J Clin Pract; 2002 Jan-Feb;56(1):68-9
Hazardous Substances Data Bank. 1,7-HEPTANEDICARBOXYLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The efficacy of azelaic acid in the treatment of lentigo maligna and melanoma has already been described and this local treatment is considered by some as an alternative agent when other forms of therapy are not realisable.
  • Here we report a case of a patient with local recurrence of a stage IV lentigo maligna melanoma of the cheek which cleared after treatment with azelaic acid cream 20%.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Dermatologic Agents / therapeutic use. Dicarboxylic Acids / therapeutic use. Hutchinson's Melanotic Freckle / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Cutaneous. Aged. Aged, 80 and over. Cheek. Female. Humans. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Lentigo maligna melanoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11831841.001).
  • [ISSN] 1368-5031
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Dermatologic Agents; 0 / Dicarboxylic Acids; F2VW3D43YT / azelaic acid
  •  go-up   go-down


5. Hardaway CA, Graham BS, Barnette DJ, Feldman BD: Embryonal rhabdomyosarcoma presenting in an adult: a case report and discussion of immunohistochemical staining. Am J Dermatopathol; 2003 Feb;25(1):45-52
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Embryonal rhabdomyosarcoma is the most common soft tissue sarcoma of childhood but is rarely seen in adults.
  • We report an embryonal rhabdomyosarcoma of the cheek in a 21-year-old Filipino man presenting as a rapidly enlarging mass.
  • The patient failed to respond to one cycle of chemotherapy after initial diagnosis and workup for metastatic disease.
  • The patient subsequently underwent radiation therapy for a total of 6,000 cGy, followed by two cycles of chemotherapy.
  • [MeSH-major] Rhabdomyosarcoma, Embryonal / secondary. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Combined Modality Therapy. Etoposide / therapeutic use. Humans. Ifosfamide / therapeutic use. Immunohistochemistry. Male. Neoplasm Proteins / chemistry. Radiotherapy, Adjuvant. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12544100.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


6. Nishimori H, Takahashi S, Nagasaki E, Kobayashi T, Yokoyama M, Shinozaki E, Mishima Y, Terui Y, Chin K, Mizunuma N, Ito Y, Inamura K, Hatake K: [An autopsied case of metastatic endocrine carcinoma of the pancreas with primary site difficult to identify]. Gan To Kagaku Ryoho; 2005 May;32(5):671-3
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 40-year-old man suffering from right cheek swelling was first diagnosed with ameloblastoma or anaplastic poorly-differentiated carcinoma of the head and neck region.
  • He received 2 courses of CDDP/TXT chemotherapy (cisplatin 75 mg/m2, docetaxel 80 mg/m2) and achieved a partial response, but his carcinoma of the pancreas recurred.
  • This case was close to a cancer with an unknown primary (CUP) site, and several favorable sub-sets of CUP have been identified, which are responsive to systemic chemotherapy.
  • Poorly-differentiated neuroendocrine carcinomas like this case are highly sensitive to chemotherapy, and a careful pathological diagnosis may clarify its sensitivity to chemotherapy and the prognosis.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / pathology. Humans. Magnetic Resonance Imaging. Male. Neoplasm Metastasis. Paclitaxel / administration & dosage. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15918570.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Savelli SL, Klopfenstein KJ, Termuhlen AM: Mucoepidermoid carcinoma of the parotid gland as a second malignant neoplasm. Pediatr Blood Cancer; 2005 Dec;45(7):997-1000
Genetic Alliance. consumer health - Mucoepidermoid carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoepidermoid carcinoma of the parotid gland as a second malignant neoplasm.
  • Thirteen years after her initial diagnosis she presented with a painless mass in her right cheek.
  • [MeSH-major] Carcinoma, Mucoepidermoid / surgery. Leukemia, B-Cell / drug therapy. Neoplasms, Second Primary / surgery. Parotid Neoplasms / surgery. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2004 Wiley-Liss, Inc.
  • (PMID = 15602710.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Monma F, Ueno S, Yamaguchi M, Tawara I, Miyazaki K, Nishii K, Nakase K, Katayama N: [Long-term remission of a nasal NK/T-cell lymphoma patient with massive involvement of the orbita and liver dysfunction]. Rinsho Ketsueki; 2009 Jan;50(1):44-8
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 49-year-old woman with high fever and diffuse swelling of the right cheek was referred to our hospital.
  • Computed tomography showed right orbital tumor with massive involvement.
  • Histopathologic examination of the biopsied right orbital tumor demonstrated extranodal NK/T-cell lymphoma, nasal-type.
  • She was treated with six courses of chemotherapy consisting of etoposide and dexamethasone with 50 Gy of concurrent involved-field radiotherapy.
  • Facial swelling and liver dysfunction improved immediately, and after five courses of chemotherapy, she achieved partial remission without any severe adverse events.
  • L-asparaginase was administered in the final course of chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Diseases / complications. Lymphoma, Extranodal NK-T-Cell / drug therapy. Lymphoma, Extranodal NK-T-Cell / radiotherapy. Nose Neoplasms / drug therapy. Nose Neoplasms / radiotherapy. Orbital Neoplasms / drug therapy. Orbital Neoplasms / radiotherapy
  • [MeSH-minor] Asparaginase / administration & dosage. Combined Modality Therapy. Dexamethasone / administration & dosage. Etoposide / administration & dosage. Female. Humans. Middle Aged. Neoplasm Invasiveness. Radiotherapy Dosage. Remission Induction. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19225229.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


9. Busam KJ, Hester K, Charles C, Sachs DL, Antonescu CR, Gonzalez S, Halpern AC: Detection of clinically amelanotic malignant melanoma and assessment of its margins by in vivo confocal scanning laser microscopy. Arch Dermatol; 2001 Jul;137(7):923-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of clinically amelanotic malignant melanoma and assessment of its margins by in vivo confocal scanning laser microscopy.
  • CONCLUSIONS: We demonstrated, for the first time, the detection of clinically amelanotic melanoma using CSLM.
  • This technique may aid in the early detection of clinically barely visible or nonpigmented melanomas and may facilitate preoperative noninvasive assessment of their margins.
  • [MeSH-minor] Aged. Biopsy. Cheek. Female. Humans. Immunohistochemistry. Infrared Rays. Leg. Melanosomes / pathology. Microscopy, Electron. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11453812.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Reiffers-Mettelock J, Ries F: A Merkel cell carcinoma of the skin. Bull Soc Sci Med Grand Duche Luxemb; 2001;(1):39-45
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 79-year old female caucasian patient presented in January 91 with a nodular lesion of the right cheek that had appeared rapidly.
  • After 3 cycles of chemotherapy, a regional radiotherapy completed the treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Merkel Cell / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. European Continental Ancestry Group. Female. Humans. Luxembourg. Lymphatic Metastasis. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11570212.001).
  • [ISSN] 0037-9247
  • [Journal-full-title] Bulletin de la Société des sciences médicales du Grand-Duché de Luxembourg
  • [ISO-abbreviation] Bull Soc Sci Med Grand Duche Luxemb
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Luxembourg
  •  go-up   go-down


11. Vorob'ev IuI, Garbuzov MM, Retinskaia II, Popov NV: [The clinical picture, diagnosis and radiation treatment principles in cancer of the buccal mucosa]. Stomatologiia (Mosk); 2000;79(1):36-8
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical picture, diagnosis and radiation treatment principles in cancer of the buccal mucosa].
  • Diagnosis and treatment of 228 patients with cancer of the buccal mucosa is analyzed.
  • For cosmetic reasons, radiotherapy (oral x-ray therapy, interstitial method, long-distance gamma beam therapy) was the method of choice.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Carcinoma / diagnosis. Carcinoma / radiotherapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / radiotherapy. Mouth Neoplasms / diagnosis. Mouth Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cheek. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Mouth Mucosa. Neoplasm Staging. Radiotherapy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10693346.001).
  • [ISSN] 0039-1735
  • [Journal-full-title] Stomatologii︠a︡
  • [ISO-abbreviation] Stomatologiia (Mosk)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] RUSSIA
  •  go-up   go-down


12. Driemel O, Berndt A, Hartmann A, Mueller-Richter UD, Bauer R, Reichert TE, Kosmehl H: [Clinical and immunohistochemical findings of intra- and extraoral angiosarcomas]. Mund Kiefer Gesichtschir; 2006 Jul;10(4):239-47
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: A clinico-pathologic study of typical symptoms of intra- and extraoral angiosarcomas and clinical course under therapy is presented as well as an analysis of the immunohistochemical differential diagnosis of the tumour specific formed spaces.
  • HISTOPATHOLOGY: For comparative analysis paraffin embedded tissue of the initial biopsies was available.
  • Detection using AP-ChemMate and Autostainer (Dako, Denmark).
  • Wide surgical excision, radiotherapy and/or antiangiogenic chemotherapy could not prevent tumour progression and death within two and a half years after primary diagnosis.
  • The tumour associated structural defect of vascular lamina with partial loss of pericytes/vascular smooth muscle cells was identified immunohistochemically by alpha-smooth-muscle-actin and for the first time by tenascin-C.
  • Oral and perioral angiosarcomas show poor prognosis despite of multimodal therapy. (2.
  • [MeSH-major] Alveolar Process. Biomarkers, Tumor / analysis. Cheek. Hemangiosarcoma / pathology. Mandibular Neoplasms / pathology. Maxillary Sinus Neoplasms / pathology. Mouth Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 1996 Dec;429(6):311-22 [8982375.001]
  • [Cites] In Vitro Cell Dev Biol. 1991 Aug;27A(8):651-9 [1717427.001]
  • [Cites] Cutis. 2005 Nov;76(5):313-7 [16422466.001]
  • [Cites] Curr Oncol Rep. 2002 Nov;4(6):515-9 [12354365.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2005 May;19(3):357-9 [15857466.001]
  • [Cites] Eur J Dermatol. 2000 Jun;10(4):300-2 [10846259.001]
  • [Cites] J Pathol. 2004 Jul;203(3):771-9 [15221936.001]
  • [Cites] Plast Reconstr Surg. 2006 Feb;117(2):687-8 [16462373.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):683-97 [9630175.001]
  • [Cites] Clin Orthop Relat Res. 1995 Apr;(313):81-91 [7543836.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4384-92 [12933583.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1061-6 [11474291.001]
  • [Cites] Mund Kiefer Gesichtschir. 2004 Mar;8(2):118-22 [15045535.001]
  • [Cites] Ultrastruct Pathol. 1997 Nov-Dec;21(6):537-44 [9355236.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):523-33 [15087672.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2003 Sep;17(5):594-5 [12941106.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):361-6 [15948172.001]
  • [Cites] FASEB J. 2005 Feb;19(2):270-1 [15579670.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):48-57 [12502927.001]
  • [Cites] Cancer. 2003 Nov 15;98(10):2251-6 [14601096.001]
  • (PMID = 16788797.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


13. Jones S, Clark G, Koleszar S, Ethington G, Mennel R, Paulson S, Brooks B, Kerr R, Denham C, Savin M, White C, Blum J, Kirby R, Stone M, Pippen J, Kitchens L, George T, Cooper B, Peters G, Knox S, Grant M, Cheek H, Jones R, Kuhn J, Lieberman Z, Savino D, Rietz C: Low proliferative rate of invasive node-negative breast cancer predicts for a favorable outcome: a prospective evaluation of 669 patients. Clin Breast Cancer; 2001 Jan;1(4):310-4; discussion 315-7
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study was designed to compare outcome in terms of disease-free survival (DFS) in women with histologically negative axillary lymph nodes and documented low proliferative rate cancer to other well-defined prognostic factors including type of adjuvant treatment.
  • At a median follow-up of 53 months, 5-year DFS for the entire group was 94% and did not differ significantly by type of systemic adjuvant treatment: none (133 patients, 95% DFS), tamoxifen (441 patients, 94% DFS), or chemotherapy with doxorubicin and cyclophosphamide (95 patients, 92% DFS).
  • We have prospectively confirmed that a low rate of proliferation as measured by SPF or MIB1 determination confers an excellent prognosis in invasive node-negative breast cancer up to 5 cm in size, regardless of adjuvant treatment.
  • [MeSH-minor] Adult. Antibiotics, Antineoplastic / therapeutic use. Antigens, Nuclear. Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Axilla. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Humans. Ki-67 Antigen / metabolism. Lymph Nodes. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Nuclear Proteins / metabolism. Prospective Studies. S Phase. Survival Rate. Tamoxifen / therapeutic use

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11899353.001).
  • [ISSN] 1526-8209
  • [Journal-full-title] Clinical breast cancer
  • [ISO-abbreviation] Clin. Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antigens, Nuclear; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 0 / Ki-67 Antigen; 0 / Nuclear Proteins; 094ZI81Y45 / Tamoxifen; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


14. Huang ZL, Li CX, Zhang FJ, Jiao DC, Wu PH, Zhang T, Wang JJ, Duan GF, Wu YX: [Short- to mid-term evaluation of CT-guided 125I brachytherapy on recurrent or metastatic head and neck cancers]. Zhonghua Yi Xue Za Zhi; 2009 Feb 10;89(5):321-4
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Thirty patients with recurrent or metastatic head and neck cancers after operation, radiotherapy, or chemotherapy, totaling 421 lesions 4.2 (2-9) cm in diameter, 23 males and 12 females, aged 56 (39-71), underwent implantation of 12-70 125I seeds (on average 33 per person) under the guidance of CT, ultrasonography, or endoscopy with an interval of 1 cm between any 2 seeds with the radioactive activity per seed of 29.6 MBq and matched peripheral dose of 90-160 Gy.
  • The overall 1-, 2-, and 3-year survival rates were 88.4%, 72.4%, and 45.2% respectively with a median survival time of 31 months.
  • The long-term complications included hyperpigmentation at operative sites (n=4), insensible feeling on lateral cheek (n=3), dryness of oral cavity (n=2), and headache combined with infection (n=1).
  • [MeSH-major] Brachytherapy / methods. Head and Neck Neoplasms / radiotherapy. Iodine Radioisotopes / therapeutic use. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19563709.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


15. Wollina U, Schönlebe J, Koch A, Haroske G: Atypical fibroxanthoma: a series of 25 cases. J Eur Acad Dermatol Venereol; 2010 Aug;24(8):943-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data on co-morbidities, treatment and outcome were obtained.
  • Medical history was positive for radiotherapy or chemotherapy in four patients.
  • CONCLUSIONS: Micrographic controlled surgery with wide 2 cm safety margins is the treatment of choice.
  • [MeSH-minor] Aged. Aged, 80 and over. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Cheek. Female. Follow-Up Studies. Forehead. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Retrospective Studies. Scalp. Treatment Outcome. Vimentin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20158588.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / Vimentin
  •  go-up   go-down


16. Calhoun K, Pommier R, Cheek J, Fletcher W, Toth-Fejel S: The effect of high dehydroepiandrosterone sulfate levels on tamoxifen blockade and breast cancer progression. Am J Surg; 2003 May;185(5):411-5
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Breast Neoplasms / drug therapy. Dehydroepiandrosterone Sulfate / blood. Dehydroepiandrosterone Sulfate / pharmacology. Estrogen Antagonists / therapeutic use. Tamoxifen / therapeutic use
  • [MeSH-minor] Adult. Age Factors. Antineoplastic Agents, Hormonal / therapeutic use. Cell Division / drug effects. Disease Progression. Drug Resistance. Female. Gonadal Steroid Hormones / blood. Humans. Middle Aged. Neoplasm Recurrence, Local. Receptors, Estrogen / analysis. Retrospective Studies. Risk Factors. Tumor Cells, Cultured / drug effects

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12727558.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogen Antagonists; 0 / Gonadal Steroid Hormones; 0 / Receptors, Estrogen; 094ZI81Y45 / Tamoxifen; 57B09Q7FJR / Dehydroepiandrosterone Sulfate
  •  go-up   go-down


17. Carter JJ, Kaur MR, Hargitai B, Brown R, Slator R, Abdullah A: Congenital desmoplastic trichoepithelioma. Clin Exp Dermatol; 2007 Sep;32(5):522-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Desmoplastic trichoepithelioma (DT) is a rare benign adnexal neoplasm considered to have follicular differentiation.
  • The most common site of occurrence is the face, usually on the cheek.
  • Histology and immunohistochemistry of incisional biopsies of the lesions were consistent with a diagnosis of DT.
  • To our knowledge, this is the first reported case of congenital DT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17459070.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Henriksson E, Baldetorp B, Borg A, Kjellen E, Akervall J, Wennerberg J, Wahlberg P: p53 mutation and cyclin D1 amplification correlate with cisplatin sensitivity in xenografted human squamous cell carcinomas from head and neck. Acta Oncol; 2006;45(3):300-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate the response of tumour growth to cisplatin treatment, in relation to p53 mutation and cyclin D1 dysregulation on DNA and protein level, biopsies from seven xenografted human squamous cell carcinomas from the head and neck were analysed with immunohistochemistry for p53 expression and cyclin D1 expression.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Cisplatin / therapeutic use. Cyclin D1 / genetics. Drug Resistance, Neoplasm. Gene Amplification. Head and Neck Neoplasms / drug therapy. Tumor Suppressor Protein p53 / genetics. Xenograft Model Antitumor Assays
  • [MeSH-minor] Animals. Cheek / pathology. Flow Cytometry. Gingival Neoplasms / drug therapy. Humans. Laryngeal Neoplasms / drug therapy. Mice. Mouth Neoplasms / drug therapy. Mutation. Neoplasms, Unknown Primary / drug therapy. Statistics as Topic

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16644573.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


19. Jouary T, Lalanne N, Siberchicot F, Ricard AS, Versapuech J, Lepreux S, Delaunay M, Taieb A: Neoadjuvant polychemotherapy in locally advanced Merkel cell carcinoma. Nat Rev Clin Oncol; 2009 Sep;6(9):544-8
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A 72-year-old man presented with a Merkel cell carcinoma (MCC) of the left cheek with concomitant nodal spread.
  • INVESTIGATIONS: Skin biopsy samples proved the MCC nature of the neoplasm in both patients.
  • Staging procedure included clinical and radiological investigations.
  • MANAGEMENT: Neoadjuvant cisplatin, etoposide and cyclophosphamide (EPC) regimen led to local control in the first patient and allowed curative surgery associated with adjuvant radiation therapy.
  • The second patient was treated by surgery plus radiation therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Merkel Cell / drug therapy. Carcinoma, Merkel Cell / pathology. Carcinoma, Merkel Cell / radiotherapy. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Humans. Male. Meta-Analysis as Topic. Middle Aged. Neoadjuvant Therapy / methods. Neoplasm Staging. Radiotherapy, Adjuvant / methods. Remission Induction. Survival Analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19707243.001).
  • [ISSN] 1759-4782
  • [Journal-full-title] Nature reviews. Clinical oncology
  • [ISO-abbreviation] Nat Rev Clin Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


20. Meier JD, Enepekides DJ, Poirier B, Bradley CA, Albala JS, Farwell DG: Treatment with 1-alpha,25-dihydroxyvitamin D3 (vitamin D3) to inhibit carcinogenesis in the hamster buccal pouch model. Arch Otolaryngol Head Neck Surg; 2007 Nov;133(11):1149-52
Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment with 1-alpha,25-dihydroxyvitamin D3 (vitamin D3) to inhibit carcinogenesis in the hamster buccal pouch model.
  • OBJECTIVE: To investigate whether systemic therapy with 1-alpha,25-dihydroxyvitamin D(3) (vitamin D(3) [hereinafter, VD(3)]) prevents tumor formation in a hamster buccal pouch model of carcinogenesis.
  • Animals were randomized to receive systemic VD(3) or no treatment and killed at 2, 6, and 14 weeks after the initiation of DMBA exposure.
  • INTERVENTIONS: A dose of 0.25 mug/kg of VD(3) via intraperitoneal injection was given to 20 animals 3 times per week.
  • Of the remaining 20 control animals, 5 received placebo vehicle injection, and 15 received no further treatment.
  • MAIN OUTCOME MEASURES: Timing, size, and number of tumors that developed in the 2 groups.
  • RESULTS: Only 1 hamster treated with VD(3) developed a confirmed neoplasm compared with 7 of the control animals (P < .01).
  • The time to onset of lesion formation was significantly delayed in those animals treated with VD(3), with a mean +/- SD time to development of 13.4 +/- 0.9 weeks, while the control animals developed lesions at 11.2 +/- 1.7 weeks (P = .02).
  • CONCLUSIONS: Systemic VD(3) therapy delays carcinogenesis in the hamster buccal pouch model.
  • [MeSH-major] Calcitriol / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Cheek. Mouth Neoplasms / drug therapy. Vitamins / therapeutic use
  • [MeSH-minor] 9,10-Dimethyl-1,2-benzanthracene. Animals. Cricetinae. Disease Models, Animal. Drug Administration Schedule. Injections, Intraperitoneal. Male. Mesocricetus

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • MedlinePlus Health Information. consumer health - Vitamins.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18025321.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vitamins; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; FXC9231JVH / Calcitriol
  •  go-up   go-down


21. Polavaram R, Fuentes CF, Shapshay SM, Wang Z: The role of laser vascular targeting and retinoic acid in oral cancer inhibition. Laryngoscope; 2003 Apr;113(4):715-9
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES/HYPOTHESIS: The study examines the role of the pulsed-dye laser at 585 nm, coupled with retinoic acid at therapeutic dose of 5.0 mg/kg body weight, in inhibiting chemically induced tumor growth in the hamster cheek pouch to determine whether pulsed-dye laser therapy can inhibit tumor growth and whether a combination of pulsed-dye laser and retinoic acid has a synergic effect on treatment efficacy.
  • METHODS: Forty-eight male golden Syrian hamsters were painted with 0.5% solution of 9,10-dimethyl-1,2-benzanthracene in acetone for 6 weeks to induce dysplasia in both sides of the cheek pouches.
  • (1) control group, (2) pulsed-dye laser treatment only (8.0 J/cm(2) and two pulses), (3) retinoic acid treatment only (5.0 mg/kg/d by intraperitoneal injection), and (4) combined pulsed-dye laser and retinoic acid treatment.
  • The treatment period was 40 days.
  • Tumor volumes were statistically different among the treatment groups.
  • There was also a statistical difference in tumor volume between the retinoic acid treatment group and the combined pulsed-dye laser and retinoic acid treatment group.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Laser Therapy. Mouth Mucosa / pathology. Mouth Neoplasms / drug therapy. Mouth Neoplasms / prevention & control. Tretinoin / therapeutic use
  • [MeSH-minor] Animals. Combined Modality Therapy. Cricetinae. Injections, Intraperitoneal. Male. Neoplasm Staging. Prospective Studies. Random Allocation

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12671434.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 91324; United States / NCI NIH HHS / CA / CA 96509
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  •  go-up   go-down


22. Meyskens FL: Development of Bowman-Birk inhibitor for chemoprevention of oral head and neck cancer. Ann N Y Acad Sci; 2001 Dec;952:116-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bowman-Birk inhibitor (BBI) is a protease inhibitor derived from soybeans that has demonstrated chemoprevention activity in many in vitro and animal systems, including the hamster cheek pouch model.
  • In the Phase IIa trial, changes in the protease activity in oral mucosal cells after BBI Concentratec (BBIC) treatment correlated with the changes in neu protein levels.
  • Additionally, evidence for a dose-related treatment effect of BBIC on oral leukoplakia was demonstrated.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Leukoplakia, Oral / drug therapy. Mouth Neoplasms / prevention & control. Trypsin Inhibitor, Bowman-Birk Soybean / therapeutic use
  • [MeSH-minor] Adult. Amino Acid Sequence. Biomarkers, Tumor. Clinical Trials, Phase II as Topic. Female. Forecasting. Genes, erbB-2. Humans. Male. Molecular Sequence Data. Mouth Mucosa / drug effects. Mouth Mucosa / enzymology. Neoplasm Proteins / analysis. Pregnancy. Receptor, ErbB-2 / analysis. Smoking / metabolism. Treatment Outcome

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11795430.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA62203; United States / NCI NIH HHS / CA / CA72294
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Trypsin Inhibitor, Bowman-Birk Soybean; EC 2.7.10.1 / Receptor, ErbB-2
  • [Number-of-references] 11
  •  go-up   go-down


23. Phan R, Phan L, Ginsberg LE, Blumenschein G, Williams MD, Esmaeli B: Durable response to chemotherapy for recurrent squamous cell carcinoma of the cheek with perineural spread. Arch Ophthalmol; 2009 Aug;127(8):1074-5
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable response to chemotherapy for recurrent squamous cell carcinoma of the cheek with perineural spread.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Cranial Nerve Neoplasms / drug therapy. Facial Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Trigeminal Nerve Diseases / drug therapy
  • [MeSH-minor] Aged. Carboplatin / administration & dosage. Cheek. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Paclitaxel / administration & dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19667357.001).
  • [ISSN] 1538-3601
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down






Advertisement